Benitec settles infringement litigation against Genscript

Published: 25-Aug-2004

International biotech company Benitec has settled its pending patent infringement case against Genscript. As part of the settlement, Genscript has taken from Benitec a worldwide non-exclusive license to make and sell DNA-directed RNAi (ddRNAi) based products. Financial details of the settlement are confidential.


International biotech company Benitec has settled its pending patent infringement case against Genscript. As part of the settlement, Genscript has taken from Benitec a worldwide non-exclusive license to make and sell DNA-directed RNAi (ddRNAi) based products. Financial details of the settlement are confidential.

Benitec has also been granted of its second UK patent related to DNA-directed RNAi (ddRNAi) technology. Patent No. GB2377221, granted on 18 August, 2004, claims compositions and methods for using ddRNAi expressed as hairpins in vertebrate animal cells. This brings the number of issued patents in Benitec's patent estate to eight. A further 65 RNAi-based patent applications are in advanced stages of prosecution in 14 other jurisdictions.

'I am pleased that we have again been able to settle an infringement dispute by the granting of a non-exclusive license to Genscript,' said John McKinley, chairman and ceo of Benitec. 'Based upon our expanding issued ddRNAi patent estate, we are committed through our licensing strategy to enable the widest use of ddRNAi in both products and research licenses and to protect both Benitec and our ddRNAi licensees.'

  

You may also like